“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin Launches Authorized Generic version of Vimovo®
Mumbai, Baltimore, March 5, 2020: Pharma major Lupin Limited (Lupin) announced the launch of the authorized generic for Horizon Therapeutics PLC’s Vimovo® (naproxen/esomeprazole magnesium) delayed-release tablets, 375 mg/20 mg and 500 mg/20 mg in the U.S.
The product is a combination of naproxen, a non-steroidal anti-inflammatory drug (NSAID), and esomeprazole magnesium, a proton pump inhibitor (PPI) indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers.
Naproxen and Esomeprazole Magnesium Delayed-Release Tablets (RLD: Vimovo®) had an annual sales of approximately USD 400 million in the U.S. (IQVIA MAT January 2020).
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupin/ | Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact -
Head – Investor Relations and Corporate Communications
Tel: +91 22 6640 8237
General Manager – Corporate Communications
Tel: +91 22 6640 2532
*Safe Harbor Statement
Vimovo® is a registered trademark of AstraZeneca UK Limited